Stifel Nicolaus Keeps Their Buy Rating on Biogen (BIIB)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen today and set a price target of $214.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Matteis covers the Healthcare sector, focusing on stocks such as PepGen Inc., Denali Therapeutics, and KalVista Pharmaceuticals. According to TipRanks, Matteis has an average return of 13.9% and a 47.69% success rate on recommended stocks.

In addition to Stifel Nicolaus, Biogen also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued on April 2. However, on the same day, Barclays maintained a Hold rating on Biogen (NASDAQ: BIIB).

Based on Biogen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.28 billion and a GAAP net loss of $48.41 million. In comparison, last year the company earned a revenue of $2.45 billion and had a net profit of $266.7 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year. Most recently, in February 2026, Priya Singhal, the Head of Development of BIIB sold 2,660.00 shares for a total of $531,547.80.